Texas Researchers Summarize Promising Research on New Mesothelioma Drug, According to Surviving Mesothelioma

Share Article

The authors of a new report on bevacizumab (Avastin) say there continues to be good evidence that the VEGF-inhibitor can boost the effectiveness of mesothelioma chemotherapy.

VEGF-Inhibitors in Mesothelioma Treatment

Bevacizumab Looks Promising for Mesothelioma

Emerging evidence also suggests...that anti-VEGF therapies may augment the effect of immunotherapy in cancer,

Researchers in Texas have released a new report summarizing the growing body of encouraging studies on anti-angiogenesis drugs like bevacizumab in the treatment of malignant mesothelioma. Surviving Mesothelioma has just published an article on the report. Click here to read the details.

A pair of doctors from the University of Texas Southwestern Medical Center summarized the findings of multiple studies on bevacizumab and other drugs that inhibit the formation of blood vessels in mesothelioma tumors.

Writing in the journal OncoTargets and Therapy, they conclude that these drugs not only help fight pleural mesothelioma tumors by choking off their blood supply, but that they may fight the asbestos cancer in another way, as well.

“Emerging evidence also suggests that VEGF may suppress T-cell-mediated immune response, and therefore, anti-VEGF therapies may augment the effect of immunotherapy in cancer,” write Pavel Levin, MD, PhD, and Jonathan Dowell, MD, of the University of Texas Southwestern Medical Center, authors of the new report.

“We have been watching the news on Avastin closely, especially since the National Comprehensive Cancer Network guidelines added it as a possible first-line mesothelioma treatment last year, along with pemetrexed and cisplatin,” says Alex Strauss, Managing Editor for Surviving Mesothelioma.

To learn more about how bevacizumab works and why it is not an appropriate treatment choice for every mesothelioma patient, see VEGF-Inhibitor Looks Promising for Malignant Mesothelioma, now available on the Surviving Mesothelioma website.

Levin, PA, and Dowell, JE, “Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date”, April 7, 2017, OncoTargets and Therapy, 2057-2066, https://www.dovepress.com/spotlight-on-bevacizumab-and-its-potential-in-the-treatment-of-maligna-peer-reviewed-fulltext-article-OTT

For more than a decade, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michael Ellis
Cancer Monthy
+1 (919) 570-8595
Email >
Follow us on
Visit website